Anphar Laboratories
Anphar Laboratories is a privately held Indian API manufacturer founded in 1987, producing WHO-GMP certified Active Pharmaceutical Ingredients, impurities, and drug intermediates for global pharmaceutical companies across 40+ countries.
- Company typePrivate
- Founded1987
- HeadquartersJammu, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Anphar Laboratories does
Anphar Laboratories Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 1987 and headquartered in Jammu & Kashmir, specializing in the development, production, and export of Active Pharmaceutical Ingredients (APIs), impurities and reference standards, and advanced drug intermediates. The company holds WHO-GMP and ISO 9001 certifications and operates a portfolio of approximately 25 APIs spanning antipsychotics (Haloperidol, Amisulpride, Trifluoperazine, Fluphenazine), antidepressants (Paroxetine, Fluvoxamine, Amoxapine), antiemetics (Metoclopramide, Prochlorperazine), NSAIDs (Benzydamine), antihistamines (Ebastine), DMARDs/bisphosphonates (Leflunomide, Risedronate Sodium), and specialty molecules (Citicoline, Acamprosate, Pantoprazole). Products are manufactured to IP, BP, USP, and EP pharmacopoeial standards in state-of-the-art facilities equipped with HPLC and GC analytical instruments.
The company's business model is B2B direct sales to pharmaceutical manufacturers and distributors, with all revenue generated through custom-priced, multi-year contracts. Its revenue streams include API sales (one-time license supply), impurities and working standards, advanced drug intermediates, and Contract Research and Manufacturing Services (CRAMS). Anphar exports to over 40 countries across Europe, Latin America, Africa, and Asia, with a documented enterprise customer base that includes Cadila Pharmaceuticals, Square Pharmaceuticals, Akums Drugs & Pharmaceuticals, Coral Labs, Medicamen Biotech, Nabi Qasim, Gedanum Pharma, INFA GmbH, and AL Andalous. The company is founder-led, with Anil Gupta serving as Founder & Managing Director alongside his son Ankit Gupta as Director and Neeru Dulloo as Executive Director; no institutional investors or external funding have been disclosed.
The company maintains an R&D function focused on novel therapeutics and process improvement, with capabilities in impurity identification and characterization that serve both internal API production and external reference-standard supply. Go-to-market relies on direct enterprise sales, a company website with inquiry forms, LinkedIn and other social channels, and participation in pharmaceutical industry events. No AI/ML, software, or digital platform capabilities are disclosed in the available data.
Anphar Laboratories firmographics
Firmographics- Name
- Anphar Laboratories
- Legal name
- Anphar Laboratories Pvt. Ltd.
- Website
- https://anphar.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Anphar Laboratories is a privately held Indian API manufacturer founded in 1987, producing WHO-GMP certified Active Pharmaceutical Ingredients, impurities, and drug intermediates for global pharmaceutical companies across 40+ countries.
- Ownership category
- akta.pro rank
Anphar Laboratories industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (API) Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
- akta.pro secondary industry
- Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)
Keywords
Where Anphar Laboratories is headquartered
LocationHeadquarters
- HQ city
- Jammu
- HQ country
- India
- HQ region
- Asia
Offices1 record
Markets served
Anphar Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Active Pharmaceutical Ingredients (APIs): Development, production, and marketing of high-quality APIs across multiple therapeutic categories including antipsychotics, antidepressants, antiemetics, anti-inflammatory, antihistamines, and bone health medications
- Impurities and Working Standards: Specialized identification, isolation, and characterization of pharmaceutical impurities and reference standards for quality control and regulatory compliance
- Advanced Drug Intermediates: Manufacturing and supply of advanced drug intermediates supporting in-house API production and serving other pharmaceutical manufacturers worldwide
- CRAMS (Contract Research and Manufacturing Services): Customized, efficient, and cost-effective contract research and manufacturing services delivered through state-of-the-art facilities and experienced scientific team
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom B2B pricing for pharmaceutical API contracts |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Anphar Laboratories product offering
Product offeringCore offering
Anphar Laboratories develops, manufactures, and exports Active Pharmaceutical Ingredients (APIs) across multiple therapeutic categories along with pharmaceutical impurities and reference standards, advanced drug intermediates, and Contract Research and Manufacturing Services (CRAMS). The company supplies 25+ APIs such as Haloperidol, Amisulpride, Paroxetine, Fluvoxamine, Metoclopramide, Leflunomide, Risedronate Sodium, and Benzydamine HCl to global pharmaceutical manufacturers from its WHO-GMP and ISO 9001 certified facility in Jammu, India.
Product overview
Anphar Laboratories is a WHO-GMP and ISO 9001 certified pharmaceutical company founded in 1987, specializing in the development, production, and export of Active Pharmaceutical Ingredients (APIs), impurities and working standards, and advanced drug intermediates. The company's product portfolio includes 25+ APIs across therapeutic categories such as Antipsychotics (Haloperidol, Amisulpride, Trifluoperazine, Fluphenazine, Prochlorperazine, Loxapine), Antidepressants (Paroxetine, Amoxapine), Antiemetics (Metoclopramide, Prochlorperazine), NSAIDs (Benzydamine), Anti-Histamines (Ebastine), DMARDs (Leflunomide), Bisphosphonates (Risedronate Sodium), and other specialty APIs. The company also offers Contract Research and Manufacturing Services (CRAMS) and R&D services for novel therapeutics development. Products are exported to 40+ countries worldwide including Europe, Latin America, Africa, and Asia.
Differentiator
Problem solved
Functional benefit
Products and services
- Active Pharmaceutical Ingredients (APIs) Portfolio High-quality Active Pharmaceutical Ingredients (APIs) across therapeutic categories including Antipsychotics (Haloperidol, Amisulpride, Trifluoperazine HCl, Fluphenazine Dihydrochloride, Prochlorperazine Maleate/Mesilate, Loxapine Succinate, Triflupromazine HCl), Antidepressants (Paroxetine HCl Hemihydrate, Anhydrous Paroxetine HCl, Fluvoxamine Maleate, Amoxapine), Antiemetics (Metoclopramide HCl Monohydrate, Prochlorperazine), NSAIDs (Benzydamine HCl), Anti-Histamines (Ebastine), DMARDs (Leflunomide), Bisphosphonates (Risedronate Sodium), Antispasmodics (Pinavarium Bromide), Diuretics (Amiloride HCl), Alpha-adrenergic agonists (Midodrine HCl), Antiulcer/GERD (Pantoprazole Sodium Sesquihydrate), Psychostimulants (Citicoline Sodium), and alcohol abstinence therapeutics (Acamprosate Calcium). Products are manufactured in IP/BP/USP/EP grades and supplied to global pharmaceutical manufacturers.
- Impurities and Working Standards Specialized pharmaceutical impurities and reference standards for quality control and drug safety verification, including Paroxetine impurities, Amiloride impurities, Fluvoxamine impurities, Haloperidol impurities, and Metoclopramide impurities. Supplied to pharmaceutical QC laboratories and manufacturers for testing and regulatory submissions.
- Advanced Drug Intermediates Specialized chemical intermediates for API synthesis, including Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate and 1-Benzyl-3-hydroxy-1H-indazole. Used to support both in-house API production and external pharmaceutical manufacturer needs worldwide.
- CRAMS (Contract Research and Manufacturing Services) Customized, efficient, and cost-effective contract research and manufacturing services delivered through state-of-the-art facilities and an experienced scientific team. Offered to pharmaceutical companies globally for custom synthesis and specialized manufacturing projects.
- Research and Development Services Cutting-edge R&D services focused on developing novel therapeutics and improving existing formulations to address unmet medical needs globally. Integrated with the company's process development and manufacturing capabilities.
- Quality Control Services In-house quality control laboratories equipped with HPLC and GC instruments for rigorous quality testing and regulatory compliance verification of APIs and intermediates.
Quantifiable outcome
- 35+ years of pharmaceutical manufacturing experience
- +1 more outcomes
Companies that use Anphar Laboratories
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Anphar Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Anphar Laboratories partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor.
- Coral LabsminorPharmaceutical manufacturing customer sourcing Active Pharmaceutical Ingredients from Anphar for their drug formulation operations.
- Akums Drugs & PharmaceuticalsminorIndian pharmaceutical company sourcing APIs from Anphar for their generic drug manufacturing operations.
- AL AndalousminorRegional pharmaceutical distribution partner in Middle East/North Africa region sourcing APIs from Anphar.
- Medicamen Biotech LtdminorIndian pharmaceutical biotechnology company sourcing Active Pharmaceutical Ingredients from Anphar.
- Nabi QasimminorPharmaceutical company sourcing APIs from Anphar for regional drug manufacturing.
- Square PharmaceuticalsminorMajor Bangladeshi pharmaceutical company sourcing APIs from Anphar for their extensive generic drug portfolio.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Anphar Laboratories competitors and assessment
Company assessmentBroad incumbents
- Laurus Labs: Indian pharmaceutical company with strong API and CRAMS operations. Comparable B2B pharmaceutical manufacturing model with broader therapeutic category coverage and a larger capital base, providing a benchmark for Anphar's growth trajectory.
- Granules India: Indian pharmaceutical manufacturer with significant API operations and formulations. Comparable in B2B API supply model and global export presence, though broader in scope and range of offerings.
- Jubilant Pharmova: Indian pharmaceutical company with API and CRAMS operations serving global markets. Comparable in pharmaceutical manufacturing capacity, regulatory standards, and customer base of international drug manufacturers.
- Divis Laboratories: Large Indian API and CRAMS major with extensive global operations. While significantly larger, Divis operates in the same small-molecule API space and serves many of the same generic pharmaceutical manufacturers that Anphar targets.
- Piramal Pharma Solutions: Major Indian CRAMS provider serving global pharmaceutical companies. Comparable to Anphar's CRAMS offering, though at significantly larger scale and with broader service capabilities including biologics.
Direct peers
- Shilpa Medicare: Indian API and formulation manufacturer with established exports to global markets. Similar in scale and customer base to Anphar, with comparable offerings in APIs across multiple therapeutic categories.
- Aurobindo Pharma: Leading Indian manufacturer of generic APIs and formulations with a large global export footprint. Direct competitor to Anphar in generic small-molecule APIs, particularly in CNS and other therapeutic categories, with similar B2B pharmaceutical supply model.
- Aarti Drugs: Indian API manufacturer with a portfolio spanning multiple therapeutic categories including anti-inflammatory, antihistamine, and CNS molecules. Highly comparable to Anphar in scale, customer base (generic pharma manufacturers), and B2B API supply model.
- Neuland Laboratories: Indian API and CRAMS provider serving global pharmaceutical manufacturers. Direct peer in small-molecule API manufacturing with similar CRAMS offerings and customer segments, including specialty and legacy molecule focus.
- Ipca Laboratories: Indian pharmaceutical company with significant API manufacturing operations across therapeutic categories. Comparable to Anphar in API manufacturing capabilities, export focus, and customer base of global generic drug manufacturers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Anphar Laboratories social profiles
Digital presenceAnphar Laboratories compliance and trust
Trust signalCompliance3 records
Anphar Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anphar Laboratories leadership team
Management profileNumber of profiles
Profiles11 records
Anphar Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anphar Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anphar Laboratories
What does Anphar Laboratories do?
Anphar Laboratories develops, manufactures, and exports Active Pharmaceutical Ingredients (APIs) across multiple therapeutic categories along with pharmaceutical impurities and reference standards, advanced drug intermediates, and Contract Research and Manufacturing Services (CRAMS). The company supplies 25+ APIs such as Haloperidol, Amisulpride, Paroxetine, Fluvoxamine, Metoclopramide, Leflunomide, Risedronate Sodium, and Benzydamine HCl to global pharmaceutical manufacturers from its WHO-GMP and ISO 9001 certified facility in Jammu, India.
Is Anphar Laboratories a public or private company?
Anphar Laboratories is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Anphar Laboratories founded?
Anphar Laboratories was founded in 1987. It employs 51 to 100 people.
Where is Anphar Laboratories based?
Anphar Laboratories is headquartered in Jammu, India, in the Asia region.
How does Anphar Laboratories make money?
Four revenue lines are on record. Active Pharmaceutical Ingredients (APIs) is the primary driver. The others are impurities and Working Standards, advanced Drug Intermediates and CRAMS (Contract Research and Manufacturing Services).
Who are Anphar Laboratories's main competitors?
Broad incumbents on record are Laurus Labs, Granules India, Jubilant Pharmova, Divis Laboratories and Piramal Pharma Solutions. Direct peers are Shilpa Medicare, Aurobindo Pharma, Aarti Drugs, Neuland Laboratories and Ipca Laboratories.
Does Anphar Laboratories have an API?
No public API is recorded for Anphar Laboratories.
What industry is Anphar Laboratories in?
Anphar Laboratories's product category is Active Pharmaceutical Ingredients (API) Manufacturing. Its primary akta.pro industry code is HLAIABAG, Generic APIs & Intermediates (Active Ingredients), with a secondary code of HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization. Its NAICS code is 3254 and its SIC code is 2833.